Yanjie Xu Qin Li Jiemin Zhao Xuefeng Ni Ping Li Wenwei Hu
10.3389/fimmu.2022.1064488
Front Immunol
2022 Nov 28;13:1064488.
lynch syndrome msh2 pd-1 inhibitors colorectal cancer germline mutation
CC BY
https://pubmed.ncbi.nlm.nih.gov/36518767/
Adenocarcinoma / drug therapy Adenocarcinoma / genetics Colonic Neoplasms / drug therapy Colonic Neoplasms / genetics Colorectal Neoplasms, Hereditary Nonpolyposis / drug therapy Colorectal Neoplasms, Hereditary Nonpolyposis / genetics
Adenocarcinoma / drug therapy Adenocarcinoma / genetics Colonic Neoplasms / drug therapy Colonic Neoplasms / genetics Colorectal Neoplasms, Hereditary Nonpolyposis / drug therapy Colorectal Neoplasms, Hereditary Nonpolyposis / genetics Case Reports Research Support, Non-U.S. Gov't Adult Germ Cells Germ-Line Mutation Humans Liver / pathology Male MutS Homolog 2 Protein / genetics Mutation MutS Homolog 2 Protein pembrolizumab MSH2 protein, human
PMC9742472
36518767
Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation
2022